Company & Sponsor Intelligence

Luye Pharma Group Ltd.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials4

Recruiting0

Completed4

Countries2

Therapeutic footprint

parkinsons

Indexed studies

NCT03589066Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease
parkinsons · United StatesPHASE1

NCT03733561A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro
parkinsons · United StatesPHASE1

NCT02055274Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease
parkinsons · United StatesPHASE1

NCT04571164A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
parkinsons · ChinaPHASE3

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →